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Background: Three main categories of persons are targeted by the French influenza vaccination strategy: all
persons aged 65 years or over, those aged less than 65 years with certain underlying medical conditions and health
care workers. The main objective of this study was to estimate rates of influenza immunization in these target
groups attending a medical consultation for two consecutive influenza seasons: 2009–2010 (seasonal and pandemic
vaccines) and 2010–2011 (seasonal vaccine).
Methods: A standardized questionnaire was mailed to 1323 general practitioners (GPs) of the Sentinelles Network,
collecting data on all patients seen on a randomly assigned day. For every patient, following information was
collected: age, gender, BMI, presence of any medical condition that increases risk of severe influenza illness, and
vaccination status for the three vaccines mentioned.
Results: Two hundred and three GPs agreed to participate and included 4248 patients. Overall, in persons with
high risk of severe influenza, the estimated vaccine coverages (VC) were 60%, (95% CI = 57%; 62%) for the seasonal
vaccine in 2010–2011, 61% (59%; 63%) for the seasonal vaccine in 2009–2010 and 23% (21%; 25%), for the
pandemic vaccine in 2009–2010. Among people aged 65 years and over (N=1259, 30%) VC was estimated for
seasonal vaccines at 72% (70%; 75%) in 2010–2011 and 73% (71%; 76%) in 2009–2010, and 24% (22%; 26%) for the
pandemic vaccine. The lowest seasonal VC were observed in younger persons (<65 years) with underlying medical
conditions, in particular pregnant women (<10%) and overweight persons (<30%).
Conclusions: Our study shows that influenza vaccination coverage among patients of the French Sentinelles
general practitioners remains largely below the target of 75% defined by the 2004 French Public Health Law, and
underscores the need for the implementation of public health interventions likely to increase vaccination uptake.
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In France, seasonal influenza immunization is recommended
to all persons aged ≥65 years and those with underlying
medical conditions that increase their risk for influenza dis-
ease or complications [1]. Before 2010, patients with severe
bronchopulmonary, cardiac, renal disease, sickle cell disease/
thalassemia, diabetes mellitus, or any immune disorder (HIV
infection, immunosuppressive drugs, cancer . . .) were
targeted by French immunization recommendations [2].
Since 2010, pregnant women (at any trimester) and over-
weight persons (BMI≥30) have been added to the list of pa-
tients that should receive the monovalent influenza A
(H1N1) 2009 vaccine and subsequently, the seasonal triva-
lent vaccine yearly [3]. Every year in France, people targeted
by seasonal influenza immunization receive an invitation
from health authorities to get a free-of–charge vaccine, ad-
ministered by their General Practitioner (GP). Despite this
large national vaccination campaign, rates of immunization
against seasonal influenza remain weak: the global vaccin-
ation coverage (VC) for the target population was 51% in
2007, 56% in 2008 and 57% in 2009, as estimated by the
National Health Insurance [4]. To our knowledge there is
no data in the literature on detailed immunization rates
among at-risk populations in general practice since the in-
fluenza pandemic occurred. The objectives of this cross-
sectional study were 1) to describe age distribution and
risk factors of severe influenza illness in patients seen on a
given day by French GPs, 2) to estimate influenza
immunization rates for two consecutive seasons (2009–
2010 and 2010–2011), and 3) to identify predictors of sea-
sonal vaccination in target groups.
Methods
Study design
We conducted a cross-sectional study among GPs of the
French Sentinelles Network, a computerized disease-
surveillance system with active volunteer physicians lo-
cated throughout mainland France, accounting for 2% of
the whole population of French GPs [5]. All 1323 GPs of
the network were contacted by email and invited to par-
ticipate to the study in May 2011. A day of participation
was randomly assigned to each GP who agreed to par-
ticipate and randomization was balanced to reflect the
distribution of the usual days of consultation from Mon-
day to Saturday, as declared by participants.
Data collection
For every patient presenting on a given day at their prac-
tice, participating GPs were asked to fill out a standardised
questionnaire on age, gender, vaccination status against
seasonal influenza (in 2009–2010 and 2010–2011), pan-
demic influenza in 2009–2010, and presence of risk fac-
tors for severe influenza illness, as defined by French
health authorities (Table 1). Data on both chronicconditions and immunization status were reported by the
GPs without any written confirmation. Data were obtained
either by asking to the patient and/or using data from
their medical records.]
In addition, data were collected on age, gender, region
of exercise for participating GPs. Regions of exercise
were categorised in rural or urban areas according to the
mean number of inhabitants (urban municipalities are
municipalities without continuous built area of 2000 in-
habitants, and those with less than half of the municipal
population is in an area of continuous built, as defined
by the French Institute of Demography [6]). GPs partici-
pating to the study were compared to the whole popula-
tion of French GPs, based on national data [7] on age,
gender, geographical area and type of practice (group or
single medical practice).
Statistical analysis and sample size calculations
Previous studies of the Sentinelles Network estimated
that on a normal day of consultation, GPs would see an
average of 20 patients [8]. With a response rate of 20%,
we calculated that we could include approximately 5,300
patients and estimate rates of immunization as low as
30% with an accuracy of 5%.
Results are expressed as the median [Interquartile Range]
for continuous variables and N (%) for categorical variables.
Immunization rates are given with their 95% confidence in-
tervals (95%CI). Predictors of immunization against seasonal
influenza in 2010–2011 were studied by fitting generalized
linear models with random intercept to the data. Vaccin-
ation against influenza in 2010–2011 was the response vari-
able and ‘GP’ effect was regarded as a random effect.
Variables analysed in the univariate analysis were: age, gen-
der, vaccination against seasonal influenza in 2009–2010,
vaccination against pandemic influenza in 2009–2010, and
number of individual risk factors for severe influenza illness
(taken as <1 or ≥2). Factors achieving a p-value < 0.20 in the
univariate analysis were included in the multivariate analysis.
A backward stepwise variable selection procedure was used
to remove factors with p-value > 0.05. Statistical analysis
was performed using the R software version 2.13 (R Devel-
opment Core Team, R Foundation for Statistical Comput-
ing, Vienna, Austria, http://www.r-project.org).
Ethics
The protocol was conducted in agreement with the
Helsinki declaration. The protocol was approved by the
ethical committee (CPP Ile de France V). We obtained
authorization from the French Data Protection Agency
(CNIL, registration number #471393) and all data trans-
mitted for statistical analysis were anonymous. Verbal
non-opposition was obtained. If a child was selected,
non-opposition for participation in the study was re-
quested from a parent (or legal guardian).
Table 1 People targeted by influenza vaccination in
2010–2011, according to French health authorities
– Age ≥ 65
– Pregnancy at any trimester
– Obesity (BMI ≥ 30)
– Broncho-pulmonary disorder
– Severe cardiac disease
– Chronic renal disease
– Sickle cell disease /thalassemia
– Diabetes mellitus
– Any immune disorder (HIV infection, immunosuppressive drugs,
cancer, . . .)
– Household contact of at-risk newborn
Privileggio et al. BMC Public Health 2013, 13:246 Page 3 of 8
http://www.biomedcentral.com/1471-2458/13/246Results
Practitioners
Of 1,323 GPs of the Sentinelles Network solicited by
email in May 2011, 262 agreed to participate (20%), and
203 (77%) returned their questionnaire. From June to
September 2011, 203 GPs included 4248 patients.
One hundred and seventy four GPs (86%) were male.
Their median age was 55 [Interquartile Range, IQR =
51–59] at the time of the study, and most (N=160, 79%)
were aged >50 years. All administrative regions of
metropolitan France were represented. One hundred
and thirty three (67%) GPs were working in rural areas,
and 86 (52%) belonged to group medical practices. On
day of participation, each GP had included 20 patients
(median, IQR = 15–25). Participating GPs were compar-
able to the whole population of French GPs with respect
to age (mean age 52 years in both, Student test p-value,














Total patients targeted by vaccine recommendationshigher proportion of men in our sample (86% and 71%
respectively, Chi-2 test p-value <0.0001).
Patients
Demographical and clinical data of patients are displayed
in Table 2. Most patients were women (56%) and their
median age was 50 [IQR= 27–68]. Of 4,248 patients in-
cluded, 1,827 (43%) were targeted by influenza vaccin-
ation, either because of age (≥65, N=1259) or the
presence of an individual risk factor of severe influenza
disease (N=568) (Table 2). The most represented indi-
vidual risk factor was obesity (N=573, 14%), followed by
diabetes mellitus (N=361, 9%), severe cardiac disease
(N=281, 7%), and chronic bronchopulmonary diseases
(N=243, 6%). Other risk factors were less represented: 5
(<1%) patients had chronic renal disease and 44 women
were pregnant. Around 2% (N=64) of study patients had
chronic immune suppression, either due to HIV infec-
tion (N=22, <1%) or other medical conditions such as
active solid cancer (N = 23), long term corticosteroid
therapy and/or other immunosuppressive drugs for
autoimmune diseases (N = 13), malignant hemopathies
(N = 9), chronic liver diseases (N = 5), or solid organ
transplantation (N = 2).
Seasonal vaccine
Overall rates of immunization against seasonal influenza
were 32%, (95%CI: 30%; 33%) in 2009–2010 and 30%
(95%CI: 28%; 31%) in 2010–2011 (chi-square p-value =
0.06, Table 3). Age distributions were not statistically dif-
ferent between the two seasons (p =0.06) (Figure 1).
Rates of immunization in patients aged ≥ 65 were 72%
(95%CI: 60%; 81%) in 2009–2010 and 73%, (95%CI: 62%;
81%) in 2010–2011 (p-value = 0.47). For both seasons,(min -max)
Patients included (N=4248)
2373 (56%)




















Patients targeted by vaccine recommendations (N=1827) 60 (57–62) 61 (59–63) 23 (21–25)
Age ≥ 65 (N=1259) 72 (70–75) 73 (71–76) 24 (22–26)
Obesity (N=256) 75 (70–80) 76 (71–81) 29 (24–35)
Severe cardiac disease (N=233) 83 (78–88) 85 (81–90) 32 (26–38)
Diabetes mellitus(N=232) 81 (76–86) 81 (76–86) 35 (28–41)
Chronic bronchopulmonary disease (N=126) 87 (81–93) 87 (81–93) 32 (23–40)
Chronic renal disease (N=31) 90 (80–100) 90 (80–100) 23 (8–39)
HIV infection (N=4) 100 (100–100) 75 (33–100) 67 (13–100)
Other immunosupression (N=18) 78 (59–97) 78 (59–97) 22 (3–41)
Age < 65 and ≥ 1 individual risk factor (N=568) 32 (28–36) 34 (30–38) 21 (17–24)
Obesity (N=317) 25 (20–30) 27 (22–32) 18 (14–22)
Severe cardiac disease (N=48) 43 (28–57) 47 (33–61) 32 (19–45)
Diabetes mellitus(N=129) 53 (45–62) 57 (49–66) 25 (17–32)
Chronic bronchopulmonary disease (N=117) 41 (32–50) 44 (35–53) 24 (17–32)
Chronic renal disease (N=5) 75 (33–100) 75 (33–100) 50 (1–99)
HIV infection (N=18) 67 (45–88) 61 (39–84) 33 (12–55)
Other immunosupression (N=24) 52 (32–73) 57 (36–77) 30 (12–49)
Pregnancy (N=44) 5 (0–11) 7 (0–14) 7 (0–15)
Household contact of at-risk newborn(N=46) 37 (23–52)* 30 (17–44)* 21 (9–34)*
*Missing data: 812.
Figure 1 Rates of immunization by age group. Bars present the rates of immunization for three influenza vaccines (seasonal 2009–2010
seasonal 2010–2011 and pandemic), and their 95%CI.
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enza were observed in adults aged ≥65 with at least one
underlying medical condition, ranging from 75% to
100% depending on the risk factor.
Conversely, VC were much lower in <65 at-risk adults.
Only 34% (95%CI: 30%; 38%) and 32% (95%CI: 28%;
36%) had been vaccinated against seasonal influenza in
2009–2010 and 2010–2011 respectively. In the three
most represented risk factors among patients aged <65
(obesity, chronic bronchopulmonary disease and dia-
betes mellitus), VC hardly reached 53-57% in diabetic
patients, 41-44% in those with pulmonary disorder, and
less than 30% in overweight persons. In patients with
chronic immune suppression, rates of immunization
were slightly higher: 52-67% (N=42). On the other hand,
less than 5% of the forty four pregnant women were
vaccinated.
In the univariate analysis, factors associated with
immunization against seasonal influenza in 2010–2011
in target groups were: to have received seasonal influ-
enza vaccine in 2009–2010 (OR=220.0, 95%CI: 131.7;
369.8), to have received pandemic influenza vaccine in
2009–2010 (OR=9.9, 95%CI: 6.9; 14.4) and to have ≥2
individual risk factors for severe influenza illness
(OR=1.8, 95%CI: 1.4; 2.4). These three predictors
remained significantly associated with immunization in
2010–2011 in the multivariate analysis (OR = 321.4
(95%CI: 221.7; 465.9) ; 1.9 (95%CI: 1.3; 2.7) and 2.9 (95%
CI: 1.7; 4.7) respectively).
Pandemic vaccine
The overall pandemic VC was estimated at 16% (95%CI:
15%; 17%) in our sample and reached 23% (95%CI: 21%;
25%) in individuals with risk factors for severe influenza
illness. Rates of immunization were higher in children aged
<15 than that observed for seasonal vaccines (p-value<10-5
for both vaccines), reaching 11% (95%CI: 8%; 15%) in the
0–5 years and 19% (95%CI: 15%; 24%) in the 5–14 years
(Figure 1). However, as compared to seasonal vaccines, pan-
demic immunization rates in adults aged ≥65 years as well
as those <65 with one risk factor were low. For example in
patients aged >65 with cardiac disease, VC were of 32%Table 4 Vaccination coverages in % (95% CI) for seasonal infl
three different studies
Methodology
Administrative data CNAMTS adm
Cross-sectional national telephone survey French Institut
Standardized survey on a randomly assigned single day in
general practice
Patients of G(95%CI: 26%; 38%) for pandemic vaccine as compared to
85% (95%CI: 81%; 90%) for the seasonal vaccine on the
same season.
Discussion
Our estimates of VC against seasonal and pandemic in-
fluenza were generally comparable or higher than that
previously reported in certain categories of patients,
such as those aged 65 and over, or with chronic cardiac,
pulmonary diseases or diabetes mellitus.
Our estimates of VC for the 2010–2011 season were
comparable to those estimated by the French National
Health Insurance for subjects below 65 years with
chronic conditions; but higher for persons aged 65 years
and over [9], as shown in Table 4. In patients aged ≥65,
who accounted for around one third of our sample, VC
were above 70% for the influenza seasonal vaccines for
both seasons, similar (76%) to that reported in another
study among patients of the French GPs in 2006–2007
season [10], but substantially higher than VC value
(61%) estimated in general population aged 65 and over
in France in 2010–2011 season [11], in Spain in 2010–
2011 (59%) and 2009–2010 (63%) [12], and in the United
States in 2009–2010 (69%) [13]. In our sample of cardio-
vascular disease sufferers, VC varied notably between the
two age groups: 43-47% below the age of 65, and 83-85%
above 65. In comparison, in Spain, in 2003, vaccination
coverages were of 17% in people aged 16–49, 34% in
those aged 50–64 and 69% in patients aged 65 years and
over [14]. In the USA, these proportions for the 1999–
2000 influenza season were of 23% (95% CI, 18%–27%),
49% (95% CI, 44%–54%), and 77% (95% CI, 74%–80%)
respectively [15]. Similar features were observed for pa-
tients with chronic respiratory diseases: whereas VC
were above 85% in those aged 65 and over, younger pa-
tients were less likely to be vaccinated (VC: 41-44%), al-
though chronic bronchopathy is a well-documented risk
factor for severe influenza. A Spanish study showed that
influenza vaccination coverage among subjects with
chronic respiratory diseases in 1993, 1995–1997 and
2001 were 45%, 46% and 44%, respectively and variables
that increased the likelihood of having been vaccinateduenza vaccine in France in 2010/2011, as estimated in
Origin of data VC for seasonal influenza




inistrative data (general population) [9] 33.1% 54.0%




Ps of the French Sentinelles Network
(present study)
32% (28–36) 72% (70–75)
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disease, poor perception of health, non-smoker status, and
being married [16,17]. Yet, another Spanish study was
conducted in early 2003 in population over 40 years of age
with Chronic Obstructive Pulmonary Disease and treated
at primary-care centers. Over 10 000 patients, 87%
reported having been vaccinated in the most recent influ-
enza campaign, therefore a rate comparable to that found
in our study in the ≥65 only. Beside socio-demographic
data, health-status related variables, and lifestyles analysis,
authors found that the factor that was most strongly asso-
ciated with influenza vaccination was a precedent vaccin-
ation against pneumococcal infection [18]. Similarly, in
diabetic patients, we report seasonal vaccine coverages of
53-57% in <65 and 81% in ≥65 patients, whereas in Span-
ish diabetic adults, VC were estimated at 57% in 2003 [19]
and only 34% among those aged <65 years in 2009–2010
[20].
Overall rate of immunization against pandemic influ-
enza A(H1N1)2009 was very low in our sample (16%,
95%CI: 15%; 17%), higher than national estimates in the
general population (<8%) [21], but close to that (17%)
reported in another French cross-sectional study
conducted among GPs in spring 2010 (the MOTIVAC
study) [22]. These results likely reflect the public percep-
tion of low risk from the disease and the negative impact
of controversies concerning the safety and quality of the
pandemic vaccines [23,24]. Distinction must be made
between GP involvement in a pandemic context and GP
involvement in a seasonal context. Indeed, in France in
the context of the H1N1 pandemic, their role was rele-
gated to second place in favor of mass vaccination in
health centers open for the event. This campaign was
considered as a failure because a very small part of the
population joined the vaccination while logistical and fi-
nancial efforts to organize it were particularly important.
Hence the importance of the involvement of the special-
ists in the promotion of vaccination in patients with spe-
cific risk factors (such as pregnancy, severe pulmonary,
cardiac and renal diseases).
In our study population, 14% of patients were obese,
and 11% in those aged <65. More than 50% of them had
no other risk factor for severe influenza. Obese poorly
vaccinated were those under <65 years for seasonal flu
and all subjects of this sample for pandemic influenza. It
must be noted that there is no data in the literature on
the obese influenza vaccination coverage. Sample sizes
were low in other target groups, thus estimates of VC
should be interpreted with caution in these categories.
Forty four pregnant women could be evaluated for both
influenza seasons in our study population. VC for sea-
sonal and pandemic influenza vaccines were particularly
low (5-7%). In the United States, were influenza vaccin-
ation is routinely recommended in all pregnant women,VC was estimated at 51% for seasonal influenza vaccine
and 47% for the pandemic influenza vaccine in 2009–
2010 [25]. Similarly, a large number of pregnant women
in the Netherlands reported to be vaccinated against
2009 influenza A (H1N1): 63% (2993 respondents/
14529 patients invited to complete an internet survey)
[26]. Influenza vaccination of pregnant women was a
focus of public health efforts during the 2009–10 season
in France. Before this season, vaccine recommendations
didn’t apply to them if they had no identified risk factor
for severe influenza. However, the VC reported here sug-
gest a poor adherence to influenza vaccination in this
category, as confirmed in another large cohort of French
pregnant women in 2009 [27], were 29% of women
reported to be vaccinated against pandemic influenza. It
might be related to the physicians and patients insu-
fficient information about the safety of the pandemic
vaccine [28].
In the 18 patients living with HIV aged 65 or less, 61-
67% declared being vaccinated against seasonal and 33%
against pandemic 2009 A/H1N1 influenza. In the US in-
fluenza vaccination coverage in HIV-Infected patients
increased from 29% in the 1990 to 42% in the 2002 sea-
son [29]. A French study reported comparable A/H1N1
vaccine coverage (44%) among HIV-infected patients
[30]. The analysis of determinants in the target groups
showed that VC for seasonal influenza in 2010–2011
was related to previous vaccinations and the number of
risk factors for severe influenza illnesses. This significant
association between vaccine uptakes was shown previ-
ously [31].
Our study has both strengths and limitation that war-
rant discussion. First, the rate of participation (20%) was
slightly lower to those reported in previous studies of
the Sentinelles network [32]. Probably, the main reason
was that participating GPs were asked to fill the ques-
tionnaire for all patients presenting at their practice on a
given day, which represented an important effort. In
addition, summer holidays covered a large part of the
data collection period. However, besides response rate,
comparison of respondents to the whole population of
Sentinel GPs did not show statistical differences neither
on on socio-demographic data nor on type of practice.
Second, general applicability of our results might be lim-
ited by the fact that the study was conducted in the spe-
cific population of French Sentinelles GPs. Comparison
of our population to the whole population of French
GPs did not show major differences neither on socio-
demographic data nor on type of practice. However, the
Sentinelles network is composed by volunteer GPs who
collect real-time epidemiological data, suggesting a
specific interest for public health, in particular for
immunization. This limitation could explain the high
vaccination rates observed, as compared to studies in
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relatively low, some target groups were less represented,
leading to wide CI for rare target groups, in particular
for HIV infection, other immunosupression, chronic
renal disease and pregnancy. Patients of these categories
probably get medical care from specialists of their
chronic disease, hence underlining the importance of
conducting specific studies in specialized medical ser-
vices. And finally, immunization data were self-reported
by the patient and/or the GPs and not written-
confirmed, leading to some degree of imprecision in
evaluation of the immunization status.
Despite these limitations, such studies among Sentinelles
GPs can be complementary to the population-based stud-
ies. Indeed, our study allowed to collect data rapidly, on a
large number of patients, and was resource-saving since
all GPs of the Sentinel Network could easily and
simulatenously be contacted via an automatic-generated
email. If necessary, such study could be renewed yearly to
follow variations of the VC from on year to another, for
example in case of occurrence of an influenza pandemic.
We also specifically described the characteristics of pa-
tients attending a medical consultation with French GPs,
therefore it could help identify populations that could be
counselled by their GPs to get vaccinated. In addition,
such design might limit recall biases compared to tele-
phone surveys. Indeed, estimation of VC was based both
on answers of patients and on data collected by the GPs
in their medical records. Usually, participation biases are
in favor of better vaccinated individuals, leading to some
over-estimation of coverage in the telephone surveys.
The prevalence of chronic conditions in our study sam-
ple was comparable to that estimated in the general popu-
lation regarding data published by the French Ministry of
Health [33] for pregnancy, obesity, diabetes mellitus, Sida-
infection and chronic cardiac diseases (prevalence esti-
mates of 1%, 13% 4%, 0.05% and 1% respectively in the
general population). Persons aged 65 and over were over-
represented in our sample, whereas prevalence of chronic
bronchopulmonary and renal diseases were low, maybe
due to underdiagnosis. This confirms that for most
chronic conditions, involvement of GPs can have a poten-
tially important impact to improve VC. On the other
hand, for patients with chronic bronchopulmonary and
renal diseases, vaccination promotion limited to GP could
be less efficient and specialists must be involved.
Conclusions
This study gives an overview of characteristics of pa-
tients seen on a given day in French general practices, as
well as estimates of rates of immunization against both
seasonal and pandemic influenza in target groups. Our
estimates of VC are generally higher than that reported
by others in the general population. GPs receive a verylarge proportion of patients targeted by vaccine recom-
mendations (great variety of chronic underlying condi-
tions and elderly persons). In addition, a lot of these
patients are not regularly followed by other physicians
who could offer vaccination (patients with obesity,
diabetes. . .). We also report that pandemic influenza VC
were lower than seasonal VC in all categories of patients.
Contrary to a standard seasonal vaccination campaign,
the administration of pandemic vaccine in 2009 in
France was not primarily assured by GPs. This under-
lines the crucial role of GPs in promoting immunization
in the community. There are some examples of success-
ful public health measures through GP. Their involve-
ment in colorectal cancer mass screening allows
identification of high risk people who can then be man-
aged with a more suitable screening protocol [34]. This
study underlines the need to consider the role to be
given to GPs in the choice and implementation of
immunization strategies.
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